InsiderTrades.com logo
World’s biggest multibillionaire investor is buying THIS by the ton [picture]
From Stansberry Research   |   Ad
Don't Buy Bullion or Mining Stocks. Do THIS Instead As gold continues to break all-time highs, many folks will run out and buy bullion or mining stocks. That's not the best way to ride this gold bull market higher. Note, this showed a 995% gain the last time we shared this same investment idea.
Click here to find out what to do.
Anthony Edward Dobranowski net worth and biography
  • LinkedIn
  • Phone
  • Email
  • Website

Anthony Dobranowski Biography and Net Worth

Director of Nuvo Pharmaceuticals
Private Business Investor. Mr. Dobranowski retired from Magna International Inc., a global automotive parts supplier, in 2007. During his employment with Magna, Mr. Dobranowski was most recently a Vice President of Magna, and prior to that held various executive positions (Vice Chairman, President and CFO) at Tesma International Inc., a publicly traded Magna subsidiary. He was instrumental in the initial public offering of Tesma in 1995, and was involved in all aspects of Tesma’s growth, with particular emphasis on financing, investor relations and M&A activity. Previous to that, Mr. Dobranowski held various senior management positions with other Magna companies. Mr. Dobranowski holds an MBA from the University of Toronto and is also a Chartered Professional Accountant.

What is Anthony Edward Dobranowski's net worth?

The estimated net worth of Anthony Edward Dobranowski is at least $97,950.00 as of August 16th, 2022. Mr. Dobranowski owns 100,000 shares of Nuvo Pharmaceuticals stock worth more than $97,950 as of April 25th. This net worth estimate does not reflect any other investments that Mr. Dobranowski may own. Learn More about Anthony Edward Dobranowski's net worth.

How do I contact Anthony Edward Dobranowski?

The corporate mailing address for Mr. Dobranowski and other Nuvo Pharmaceuticals executives is 6733 MISSISSAUGA ROAD SUITE 800, MISSISSAUGA A6, L5N 6J5. Nuvo Pharmaceuticals can also be reached via phone at (905) 673-6980 and via email at [email protected]. Learn More on Anthony Edward Dobranowski's contact information.

Has Anthony Edward Dobranowski been buying or selling shares of Nuvo Pharmaceuticals?

Anthony Edward Dobranowski has not been actively trading shares of Nuvo Pharmaceuticals during the last ninety days. Most recently, on Friday, May 28th, Anthony Edward Dobranowski bought 6,000 shares of Nuvo Pharmaceuticals stock. The stock was acquired at an average cost of $1.45 per share, with a total value of $8,700.00. Following the completion of the transaction, the director now directly owns 62,181 shares of the company's stock, valued at $90,162.45. Learn More on Anthony Edward Dobranowski's trading history.

Who are Nuvo Pharmaceuticals' active insiders?

Nuvo Pharmaceuticals' insider roster includes Anthony Dobranowski (Director), and Jesse Ledger (Senior Officer). Learn More on Nuvo Pharmaceuticals' active insiders.

Anthony Edward Dobranowski Insider Trading History at Nuvo Pharmaceuticals

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
5/28/2021Buy6,000$1.45$8,700.0062,181
5/26/2021Buy1,181$1.50$1,771.5056,181
5/20/2021Buy10,000$1.60$16,015.0055,000
12/22/2020Buy9,000$0.86$7,740.0019,000
11/20/2020Sell8,181$0.81$6,626.6110,000
11/18/2020Sell24,000$0.83$19,920.0018,181
3/5/2020Buy2,915$0.84$2,448.6042,181
11/14/2014Sell3,846$6.97$26,803.54
See Full Table

Anthony Edward Dobranowski Buying and Selling Activity at Nuvo Pharmaceuticals

This chart shows Anthony Edward Dobranowski's buying and selling at Nuvo Pharmaceuticals by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Nuvo Pharmaceuticals Company Overview

Nuvo Pharmaceuticals logo
Nuvo Pharmaceuticals, Inc. is a pharmaceutical company, which is engaged in developing innovative therapeutic pharmaceutical products. It operates through the following segments: Commercial Business, Production and Service Business, and Licensing and Royalty Business. The Commercial Business segment includes Blexten, Cambia, the canadian business for Resultz and Suvexx, and mature assets. The Production and Service Business segment supplies Pennsaid to Horizon for the U.S. market and is engaged in ongoing partnering efforts for Pennsaid. The Licensing and Royalty Business segment engages in the selling of Vimovo. The company was founded on August 22, 1983 and is headquartered in Mississauga, Canada.
Read More

Today's Range

Now: $0.98
Low: $0.98
High: $0.98

50 Day Range

MA: $0.98
Low: $0.98
High: $0.98

2 Week Range

Now: $0.98
Low: $0.42
High: $1.25

Volume

N/A

Average Volume

11,250 shs

Market Capitalization

$11.17 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.98
World’s biggest multibillionaire investor is buying THIS by the ton [picture]
From Stansberry Research   |   Ad
Don't Buy Bullion or Mining Stocks. Do THIS Instead As gold continues to break all-time highs, many folks will run out and buy bullion or mining stocks. That's not the best way to ride this gold bull market higher. Note, this showed a 995% gain the last time we shared this same investment idea.
Click here to find out what to do.